HTG Announces Appointments of John Wineman and Thomas Vasicek, Ph.D.
HTG Announces Appointments of John Wineman as Vice President New Business Development–Western Region and Thomas Vasicek, Ph.D. as Vice President Clinical Programs and Product Innovation
TUCSON, Ariz., August 31, 2010 – HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced the appointments of John Wineman as Vice President New Business Development, Western Region and Thomas Vasicek, Ph.D., as Vice President Clinical Programs and Product Innovation.
Mr. Wineman will be responsible for commercial sales and new business growth for the western region of North America and Asia. “John has a tremendous background in Life Science Research and Diagnostics markets as well as a successful track record in business development, sales and marketing roles,” said BJ Kerns, Senior Vice President of HTG. “At HTG, he will play a key role in accelerating our growth and building new business relationships.”
Prior to joining HTG Mr. Wineman served as Director of Business Development for the FEI company’s Life Science Market Division. Previously, he served as Director of Strategic Marketing and Director of Corporate Development for Roche Diagnostics Group, Ventana Medical Systems Division. Mr. Wineman also held a business development role at LifeSpan Biosciences and sales management roles at Becton Dickenson and Bio-Rad Laboratories. He holds an MBA from San Diego State University and a BS in Biology from Oregon State University.
Dr. Vasicek will be responsible for leading HTG’s clinical programs, working as scientific lead with key pharma and academic collaborations and contracts as well as establishing the company’s new assay innovation roadmap. “Tom has made major contributions to medical science throughout his career; his background and experience will help propel HTG’s entrance into the molecular diagnostics market,” said TJ Johnson, HTG’s CEO. “As head of our clinical programs and diagnostic innovations, Tom will play a pivotal role in advancing HTG’s technology into new markets and applications.”
Prior to joining HTG Dr. Vasicek served as Senior Director Medical Innovation for Ventana Medical Systems, a member of the Roche Group, where he led new assay development for oncology prognostics and therapy guidance. Previously, he served as Senior Director, Bioscience Technology Development at Medtronic, Inc. Dr. Vasicek also served as Vice President, Business Development for Solexa, Inc. / Lynx Therapeutics; CSO for LabSeek Scientific Collaboration; Director, Commercial Technology for Corning Advanced Life Science Products; Senior Scientist in Target Discovery for Millennium Pharmaceuticals; and a visiting scientist at the Whitehead Institute. Dr. Vasicek was a Postdoctoral Research Fellow at Princeton University. He received his Ph.D. in Genetics from Harvard University and a B.S. in Chemistry from the Massachusetts Institute of Technology.
“I am extremely excited to add two new members to the HTG leadership team in John Wineman and Tom Vasicek,” added TJ Johnson. “These appointments validate the progress HTG has made as a personalized healthcare company and provide us the executive bandwidth to accelerate our growth into molecular diagnostics.”
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at http://www.htgenomics.com.
Luminex Corporation and HTG Launch qBead Assay
LUMINEX CORPORATION AND HIGH THROUGHPUT GENOMICS
LAUNCH THE QBEAD ASSAY
LUMINEX TO DISTRIBUTE CO-DEVELOPED CUSTOM
GENE EXPRESSION PRODUCT
AUSTIN, Texas and TUCSON, Arizona – May 18, 2010 – Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA™), today launched a new custom gene expression product, the qBead Gene Expression Assay (qBead Assay). The companies co-developed the product and have signed an exclusive distribution agreement in which Luminex will begin offering it to the research community.
“Advances in discovery through sequencing and high-density arrays have driven significant growth in the mid-plex custom gene expression research market,” said TJ Johnson, CEO of HTG. “Scientists in this area validate gene expression signatures and screen established panels. They often need custom assays that allow them to quickly and accurately measure a select set of genes in many samples. With the qBead Assay, HTG and Luminex have joined forces to meet this need.”
The new qBead Assay places HTG’s proven qNPA™ chemistry on the Luminex xMAP® Technology multiplexing platform. The result is a high-throughput assay with a simplified workflow that requires no extractions, cDNA synthesis or amplifications. The qBead assay is uniquely suited for scientists who need to get high quality gene expression data from degraded samples or difficult samples such as Formalin-Fixed Paraffin-Embedded (FFPE) and other fixed tissues where RNA quality is an issue.
Researchers can order a qBead Assay that is custom-tailored to their genes of interest and optimized for their sample type.
“The combination of xMAP Technology from Luminex and the qBead Assay represents an advance for many scientists, including cancer researchers who perform retrospective studies on large numbers of archived samples,” said Patrick J. Balthrop, president and CEO of Luminex. “Luminex is excited to partner with HTG to leverage our scientific and technical expertise and respective technologies to create high-throughput, custom assays that will advance the work of researchers in the critical, growing mid-plex custom gene expression research arena.”
Custom qBead Assays employ Luminex’s MagPlex® magnetic beads. They allow multiplexed measurement of multiple gene expression signatures per sample that have the opportunity to run on the thousands of Luminex 100/200™ instruments installed, and can utilize the high-throughput, 500-gene multiplexing capability of the new Luminex FLEXMAP 3D® instrument.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company’s xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company’s xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at www.luminexcorp.com.
HTG Signs Collaboration Agreement with John Wayne Cancer Institute
HTG SIGNS COLLABORATION AGREEMENT WITH JOHN WAYNE CANCER INSTITUTE
Tucson, Ariz.—April 28, 2010—HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Dept Molecular Oncology, Dave S. B. Hoon, PhD Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG’s qNPA technology in classical surgical pathology samples.
Dr. Hoon is investigating the implications of differential gene expression in human diseases such as melanoma. The ability to distinguish between early stage primary melanomas and benign nevi is important given the difficulty that is sometimes encountered in diagnosing primary melanoma and in turn managing the disease better before onset of clinical metastasis.
“Our work with Dr. Hoon in this research program will further establish HTG’s qNPA technology as a useful and robust diagnostic platform. We are excited to be part of this collaboration and believe our multiplex gene expression platform coupled with our extraction free method of analyzing formalin fixed paraffin embedded (FFPE) samples makes us ideally suited for this important application”, said TJ Johnson, President and CEO, HTG.
“The program will provide new approaches to improve diagnosis of early stage primary cutaneous melanomas. This area of diagnosis has been problematic whereby, novel sensitive molecular diagnosis approaches may be more informative and accurate”, said Dr. Hoon.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com
About John Wayne Cancer Institute at Saint John’s Health Center
Since 1981, the John Wayne name has been committed by the Wayne family to groundbreaking cancer research and education in memory of their father, who died of cancer. The John Wayne Cancer Institute has received worldwide acclaim for advances in melanoma (skin cancer), breast and colon cancer as well as for immune therapy of cancer. Other areas of research include prostate and liver cancer. With its unique ability to rapidly turn scientific breakthroughs into innovative approaches to treatment and early detection, the JWCI provides immediate hope to cancer patients around the globe.
HTG’s qNPA™ Technology selected for BARDA Grant
ASU leads $40 million effort to rapidly assess radiation exposures
Dec. 21, 2009
TEMPE, Ariz.–Arizona State University will lead a $40.8 million, multi-institutional research program to develop systems that would rapidly measure an individual’s level of exposure to radiation in the event of a radiological or nuclear incident. In the event of a large-scale disaster, such a system would ensure that first responders have the information necessary to provide appropriate medical treatment.
The five-year contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) emphasizes the development of prototypes that would enable more rapid triage of patients than is currently possible.
“With the proliferation of advanced radiological materials in hospitals, clinics or nuclear facilities throughout the world, the risks and threats of a ‘dirty bomb’ incident or similar nuclear disaster remains very real,” said Carl Yamashiro, PhD, the principal investigator at ASU’s Biodesign Institute who will direct the effort. “We have assembled a dream team of institutions and companies to catalyze our team’s research and discovery efforts, and translate the advances into a field-deployable technology.”
ASU will oversee the research program management, coordination and integration necessary for efficient and effective development of the system.
“Arizona State University has focused its world-class research enterprise on solving many of the most serious problems facing humanity,” said ASU President Michael M. Crow. “This award recognizes our leadership in research that involves the coordinated effort of a large, multi-disciplinary, complex scientific skill set and our capability of delivering on this technological promise to the ultimate benefit of society.”
The development of prototypes incorporates key technologies that build on the research, development and manufacturing strengths of the partners. The effort involves prestigious local and national institutions and companies including: the Translational Genomics Research Institute (TGen), Columbia University, High Throughput Genomics, Inc., Tecan Group, Ltd, University of Arizona, Scottsdale Cancer Research Institute, and the University of Illinois, Chicago.
The goal of the project is to deliver a Biodosimetry Assay System that would assess the amount of ionizing radiation an individual had absorbed in the event of exposure. Currently, no rapid, high-throughput system exists to measure the radiation dose of individuals within a large population.
“The beauty of this system is its versatility,” said Yamashiro. “Not only will we be developing a system for the effective response to a nuclear or radiologic event that could affect a large population but the high-throughput platform can also be used to advance genomics testing and other routine laboratory procedures measuring gene expression levels.”
Developing the system requires utilizing a biomarker signature set based on gene expression markers.
This set of markers will provide a distinct indicator for the level of absorbed radiation. The system will be capable of analyzing 2,000 blood samples in a day with an 8-hour turnaround for individual measurements to enable appropriate medical triage.
The system is designed to be comprehensive in scope, including specialized collection cartridges with which first responders can easily perform field collection of blood samples, a high-throughput assay system, and software for data collection and interpretation of results. The team will also work with government entities including the Food and Drug Administration on the implementation of the system once the prototype has been demonstrated to perform the desired tasks.
The latest effort builds on the achievements of a five-year, $25 million Center for Medical Countermeasures Against Radiation (CMCR), involving research by ASU, TGen and Columbia University. The CMCR was one of eight established by the National Institutes of Health in 2005 in response to increased concerns about radiological disasters from terrorism and illicit trafficking of radioactive materials. The CMCRs conducted foundational research and feasibility studies for such technologies and countermeasures, as well as for related fundamental research for medical options to treat the variety of acute and long-term injuries that can result from nuclear or radiological attacks.
Roche and High Throughput Genomics Partner for Advanced Gene Expression Analysis Solution
Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) and High Throughput Genomics, Inc. (HTG), provider of the quantitative Nuclease Protection Assay (qNPA), have entered into a supply agreement. Under the agreement, Roche NimbleGen will provide HTG with high density, multiplex DNA microarray slides for advanced gene expression analysis.
HTG will apply the company’s quantitative nuclease protection assay (qNPA) process to the microarrays to enable researchers to quickly and efficiently measure the gene expression levels in a variety of sample types. The agreement enhances HTG’s existing service capability offering with the ability to take a broader look at gene expression through the multiplex capability of the Roche NimbleGen microarrays. Sample preparation using qNPA technology allows for a much simpler, more cost-effective workflow versus traditional labeling methods, while the Roche NimbleGen multiplex technology offers a cost-effective high density microarray providing in depth gene expression information.
“HTG’s agreement with Roche NimbleGen affords us the opportunity to provide our customers with customizable content and an attractive sample preparation and processing format. Compared with other vendors, Roche NimbleGen was able to offer us unique and differentiated array synthesis and formatting capabilities that best meet our client needs,” said T.J. Johnson, president and CEO, HTG. “The combination of low cost, flexibility, and high throughput means HTG’s customers can derive substantial benefits quickly and we can increase the plex in the analysis process as needed.”
Gerd Maass, CEO of Roche NimbleGen said, “The partnership with HTG showcases the strengths of the two companies and the flexibility of the NimbleGen Arrays by pairing two innovative technologies to provide flexibility, time savings, and cost savings while offering the significant in depth genetic information that our high density arrays provide.”
For more information on Roche NimbleGen microarrays, go to www.nimblegen.com.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target evaluation; HTS lead optimization, metabolism and toxicology. HTG’s platform is highly flexible and designed automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
All trademarks used or mentioned in this release are protected by law.
NIMBLEGEN is a trademark of Roche.
HTG ANNOUNCES AVAILABILITY OF 96 MAX GENE EXPRESSION ASSAY
HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) today announced the launch of the quantitative Nuclease protection assay (qNPA™) 96 Max gene expression assay at the American Association of Cancer Research (AACR) annual meeting. This new testing configuration enables the measurement of 46 genes in a 96 well Array Plate. The offering provides researchers with the ability to analyze a larger number of gene signatures for research and clinical validation work in academic and translational medicine.
The 96 Max gene expression automated assay is based on HTG’s proven ArrayPlate technology platform, which allows researchers to investigate a larger set of genes with greater precision than traditional gene expression assays. The technology allows academic researchers to quickly and efficiently measure gene expression levels of mRNA and miRNA in a variety of cell and tissue types including formalin-fixed, paraffin-embedded (FFPE) samples.
The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect “HTG’s new assay offering enables our academic researchers, who are conducting clinical and basic research, to essentially unlock information from sample types that were previously very challenging and near impossible to evaluate accurately,” said BJ Kerns, VP Strategic Marketing and Business Development, HTG. “This is yet another expansion of our ArrayPlate platform. We devised this unique testing format to accommodate the needs of academic researchers who are evaluating tumor stratification, pathway and outcome schemes, as well as chemosensitivity.”
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com
HTG and CRL Form Partnership
HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) and service partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL Global Services), provider of testing
services for toxicology, molecular diagnostics, clinical trials, bioanalytics, and insurance today
announced they signed a multi-year agreement. Under the terms of the agreement, CRL Global
Services will provide CLIA certified laboratory services for HTG’s pharmaceutical, biotech and
academic clients.
HTG’s quantitative nuclease protection assay (qNPA™) is an automated assay that allows
researchers to quickly and accurately measure gene expression levels of mRNA and miRNA in
cells, blood, saliva and tissues with minimal hands-on time. Using HTG’s reagent kits and
equipment, CRL Global Services will evaluate samples or sample plates using HTG’s qNPA
ArrayPlate technology in their CLIA laboratory.
“Collaborating with CRL Global Services was a natural fit for HTG. CRL Global Services has a
strong, long-standing reputation for providing state-of-the-art CLIA testing services. In forging
this relationship, HTG is now able to offer our pharmaceutical, biotech and academic customers
a more seamless and comprehensive service offering,” said TJ Johnson, president and CEO,
HTG. “HTG’s clients are focused on stewarding gene signatures from the research laboratory to
the clinic and CRL Global Services brings a level of expertise in analysis of data that is optimal
for the FDA submission step of the process.”
“CRL Global Services is pleased to be the CLIA-certified laboratory service provider for HTG’s
qNPA technology,” said Tim Sotos, Chairman and CEO of CRL Global Services. “This
collaboration leverages CRL Global Services’ core competency as a leading service provider
and HTG’s robust technology.”
CRL Global Services’ Executive Director of Molecular Diagnostics, Dr. Heather Newkirk said,
“this unique technology from HTG enables a customized gene expression product which
partners well with CRL Global Services’ expertise in offering quality molecular services. We
look forward to working with HTG to provide qNPA services to customers world-wide.”
HTG’s assay technology will be exhibited at CRL Global Services’ Booth #626 at the Molecular
Medicine Tri-Conference in San Francisco from February 25-27, 2009. In addition, Bruce
Seligmann, Ph.D., Founder, Board Member and Chief Science Officer, VP R&D, HTG will be
presenting a talk, “New Generation Predictive Multiplexed Gene Expression Diagnostics: Case
Studies in Non-Hodgkin’s Lymphoma” on Thursday, February 26 at 4:00 p.m.
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug
discovery programs, including target validation; HTS lead optimization, metabolism, toxicology
and clinical development. HTG’s platform is highly flexible and designed automation-friendly; it
allows scientists to test any sample, including fixed tissues, without RNA extraction or target
amplification. The technology is ideal for detecting small, yet important changes in gene
expression levels which other gene expression platforms cannot reliably detect.
CRL Global Services will offer the qNPA technology as a service to HTG clients in CRL’s CLIAcertified
Molecular Diagnostics laboratory beginning spring 2009.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice
Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital.
Additional information is available at www.htgenomics.com.
About Clinical Reference Laboratory, Inc (CRL Global Services)
Established in 1979, CRL Global Services is a privately held reference laboratory in Lenexa,
Kansas offering leading-edge testing services in the areas of Clinical Trials, Corporate Wellness
Programs, Genomics, Insurance, Molecular Diagnostics, BioAnalytics and Toxicology. CRL is
one of the largest single-site laboratories in the country and analyzes over 80 million tests
annually. Additional information is available at www.crlcorp.com.
HTG Collaborates with HC-LITT
HTG SIGNS COLLABORATION AGREEMENT WITH HARVARD CATALYST LABORATORY FOR INNOVATIVE TRANSLATIONAL TECHNOLOGIES AT HARVARD MEDICAL SCHOOL
Tucson, Ariz.—December 1, 2008—HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced a collaboration agreement with researchers at Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) at Harvard Medical School. Under the terms of the agreement, HTG and HC-LITT will collaborate to generate a novel microRNA biogenesis assay that can measure expression of both pre-microRNA (miRNA) precursors, mature-microRNAs and regulated RNA using HTG’s qNPA™ (quantitative Nuclease Protection Assay) technology.
Researchers at the HC-LITT are investigating the implications of differential microRNA expression in human diseases such as cancer. MicroRNAs are singlestranded functional RNA species encoded in the human genome that regulate protein expression of numerous gene products. HC-LITT will utilize HTG’s technology to evaluate regulation of miRNA biogenesis by established oncogenic cell signaling pathways in order to develop novel diagnostic markers and therapeutic targets for the molecular characterization and treatment of cancer.
“We selected HTG’s technology due to the high precision and sensitivity of the product platform,” said Winston Patrick Kuo, Director, Harvard Catalyst Laboratory for Innovative Translational Technologies at Harvard Medical School. “I’m looking forward to utilizing HTG’s gene expression assay technology and imagers for HC-LITT’s research initiatives.”
HTG’s qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform is highly flexible and designed for high throughput automation; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.
About Harvard Catalyst Laboratory for Innovative Translational Technologies
The Harvard Catalyst Laboratory for Innovative Translational Technologies (HC-LITT) is scaling existing infrastructure to support translational research by providing early access to enabling, leading-edge genomic and proteomic technologies. The goal of the HC-LITT is to facilitate innovative, technologic contributions to novel translational research. The development of unique methods is pivotal to identifying nascent methodologies to diagnose and treat human disease. The collaborative research model is designed to bring together a myriad of innovative technologies in one place and put them to use in the hands of inventors and thought leaders.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
Fred Pollock Joins HTG
HTG NAMES FREDRICK POLLOCK VP OF CORPORATE DEVELOPMENT
Tucson, Ariz.—November 24, 2008— HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) system and service partner for the life sciences industry, today announced it has appointed Fredrick L. Pollock to Vice President of Corporate Development. Pollock will be responsible for leading commercial sales efforts in the academic and research markets, spearheading efforts for bio-marker and signature discovery collaborations and supporting commercialization efforts for the company’s mid-density array product line.
Over the past eight years, Pollack has served in management, sales and business development roles most recently as Director of Strategic Businesses and Translational Medicine at Affymetrix, Inc., a leading microarray technology vendor. His accomplishments include implementing a global alliance management program, developing strategies for sales expansions, launching several partner clinical laboratory improvement amendments (CLIA) certified clinical tests, and securing multi-millions in additional sales.
“Fred brings a wealth of industry knowledge and expertise to our leadership team and he will help us accelerate our commercial and corporate development efforts,” said TJ Johnson, President and CEO, HTG. “HTG’s portfolio strategy is to leverage the precision of the qNPA assay into the mid-plex market and establish the assay as a new standard for gene expression based diagnostics. Fred’s background is perfectly suited to help us in these specific areas.”
“I am eager to work with the HTG management team and build on the proven success of HTG’s platform to further expand the company’s customer base,” said Fred Pollock. “With my biotechnology and translational medical industry experience this was an ideal fit. I look forward to contributing to HTG’s future success in my new capacity.”
Prior to Affymetrix, Pollock worked at Amersham Pharmacia Biotech, now part of GE Healthcare, for 11 years. He most recently served as a business unit manager where he was responsible for managing sales in the central United States. He also held positions at The University of Texas Southwestern Medical Center and Photon Marketing.
Pollock earned a B.A. in Molecular Biology from the University of North Texas. HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.
About HTG
Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at www.htgenomics.com.
Upcoming shows
Vienna, Austria
San Jose, CA
Vienna, Austria
San Jose, CA
